Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). (Q41080253)
Jump to navigation
Jump to search
scientific article published on December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). |
scientific article published on December 2015 |
Statements
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) (English)
Tomoya Mita
Naoto Katakami
Hidenori Yoshii
Tomio Onuma
Hideaki Kaneto
Takeshi Osonoi
Toshihiko Shiraiwa
Keisuke Kosugi
Yutaka Umayahara
Tsunehiko Yamamoto
Hiroki Yokoyama
Nobuichi Kuribayashi
Hideaki Jinnouchi
Masahiko Gosho
Iichiro Shimomura
Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial